Potent corticosteroid
Betamethasone
Brand names: Betnesol, Celestone, Betnovate (topical)
Adult dose
Dose: Antenatal lung maturation: 12mg IM ×2 doses 24h apart; oral / topical / IV per indication
Route: Oral / IM / IV / Topical / Eye / Ear
Frequency: Per indication
Clinical pearls
- RCOG GTG: antenatal corticosteroids 24+0–34+6 weeks (consider up to 35+6) for fetal lung maturation
- BAD topical steroid potency ladder — betamethasone valerate 0.1% potent
- Tapering important for prolonged courses
Contraindications
- Systemic infection (untreated)
- Live vaccines
- Hypersensitivity
Side effects
- Cushingoid features (long-term systemic)
- Adrenal suppression
- Hyperglycaemia
- Hypertension
- Osteoporosis
- Mood change
- Topical: skin atrophy, telangiectasia, striae, perioral dermatitis, periorificial dermatitis
Interactions
- Strong CYP3A4 inhibitors
- Live vaccines
- NSAIDs (GI bleeding)
- Diabetic medications
Monitoring
- Glucose
- BP
- Bone health
- Adrenal function (long-term)
- Skin atrophy (topical)
Reference: BNF; RCOG GTG 7; BAD; https://bnf.nice.org.uk/drugs/betamethasone/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016